Overview
Dr. Andrew Nixon is Professor of Medicine in the Department of Medicine/Division of Medical Oncology at Duke University. He holds a BS in chemistry from Miami University, a PhD in biochemistry from Wake Forest University, and an MBA with a focus on healthcare management from Duke University/Fuqua School of Business. He is a nationally recognized expert in the development of cancer biomarkers and correlative science, with extensive experience leading large multi-center biomarker analyses. Dr. …
Current Appointments & Affiliations
Professor in Medicine
·
2021 - Present
Medicine, Medical Oncology,
Medicine
Member of the Duke Cancer Institute
·
1998 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Publications
Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial).
Journal Article Clin Cancer Res · March 17, 2025 PURPOSE: Mesothelin (MSLN) is highly expressed in high-grade serous/endometrioid ovarian cancers (HGOC). Anetumab ravtansine (AR) is an antibody-drug conjugate directed at the MSLN antigen with a tubulin polymerization inhibitor. We assessed the safety, ac ... Full text Link to item CiteCharacterization of the Biological Variability of the Angiome Biomarkers over Time in Healthy Participants.
Journal Article Cancer Epidemiol Biomarkers Prev · January 9, 2025 BACKGROUND: Biomarker analyses are an integral part of cancer research. Despite the intense efforts to identify and characterize biomarkers in patients with cancer, little is known regarding the natural variation of biomarkers in healthy populations. Here ... Full text Link to item CiteSupplementary Table S5 from Characterization of the Biological Variability of the Angiome Biomarkers over Time in Healthy Participants
Other · January 9, 2025 <p>Supplementary Table S5 shows three potential measures of variance.</p> ... Full text CiteRecent Grants
Targeting Hepatocyte Senescence to Improve NAFLD
ResearchAdvisor · Awarded by National Institute of Diabetes and Digestive and Kidney Diseases · 2024 - 2029Drug Development for Dystonia
ResearchCo Investigator · Awarded by Department of Defense · 2023 - 2027Duke ACS Institutional Research Grant
ResearchSignificant Contributor · Awarded by American Cancer Society, Inc. · 2024 - 2026View All Grants
Education, Training & Certifications
Duke University ·
2007
M.B.A.
Wake Forest University ·
1997
Ph.D.